RGLS

Regulus Therapeutics Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website regulusrx.com
Employees(FY) 29
ISIN US75915K3095

Performance

-0.62%

+11.97%

-7.02%

-35.89%

+24.22%

YTD

+20.45%

Profile

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of RGLS 2024-12-20

The Moving Average Score of 63 indicates a bullish sentiment, while the Oscillators Score of 46 and Technical Score of 55 suggest a more neutral outlook. Overall, the combined scores reflect a cautiously optimistic sentiment in the stock, driven primarily by the strong moving average performance.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of RGLS

Stock Rank

Recent News & Updates

2024-11-25 19:00
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences(Prnewswire)
2024-11-07 04:13
Regulus: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-07 03:05
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates(Prnewswire)
2024-10-28 18:01
These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts(Yahoo Finance)
2024-10-07 20:00
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Prnewswire)
2024-08-27 20:00
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences(Prnewswire)
2024-08-08 05:19
Regulus: Q2 Earnings Snapshot(Yahoo Finance)
2024-08-08 04:05
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates(Prnewswire)
2024-08-05 20:00
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference(Prnewswire)
2024-07-08 20:00
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences(Prnewswire)
2024-06-23 19:00
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Prnewswire)
2024-06-03 20:00
Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes(Prnewswire)
2024-05-15 20:00
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer(Prnewswire)
2024-05-09 10:57
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-09 05:16
Regulus: Q1 Earnings Snapshot(Yahoo Finance)
2024-05-09 04:05
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates(Prnewswire)
2024-05-06 18:00
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028(Investorplace)
2024-05-05 20:00
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Prnewswire)
2024-04-29 20:00
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series(Prnewswire)
2024-03-22 17:33
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements(Yahoo Finance)
2024-03-21 10:53
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-21 04:22
Regulus: Q4 Earnings Snapshot(Yahoo Finance)
2024-03-21 04:05
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates(Prnewswire)
2024-03-13 00:09
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study(Zacks)
2024-03-11 18:32
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity(Prnewswire)
2024-03-11 18:30
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Prnewswire)
2024-01-02 03:05
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Prnewswire)
2023-11-21 19:00
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference(Prnewswire)
2023-11-09 03:32
Regulus: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-09 03:05
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.